The fifth batch of countries organized the centralized procurement of medicines to produce the results of the proposed selection

On June 23, under the organization and guidance of the National Medical Insurance Bureau and other relevant departments, all provinces across the country formed an alliance to carry out the fifth batch of nationally organized drug centralized procurement in Shanghai, which produced the results of the proposed selection

This collection of products covers common diseases such as hypertension, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, and chronic disease drugs, as well as drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.

Pharmaceutical companies attach great importance to this centralized procurement.

According to reports, this centralized procurement adheres to the basic principles of "quantity and price linkage, integration of recruitment and procurement" and the working mechanism of "national organization, alliance procurement, platform operation", and further fine-tunes and perfects the rules: first, pay more attention to selected products Supply guarantee, further clarify the company's responsibility to guarantee supply, and introduce provisions to determine candidate companies

Since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug procurement, covering 218 varieties, and involving a market capacity of 220 billion yuan

In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people